Alkacit: Uses, Dosage & Side Effects

What Is Alkacit and What Is It Used For?

Alkacit contains potassium citrate, a urinary alkalinizer that raises urine pH and increases citrate excretion. It is used to treat and prevent kidney stones (nephrolithiasis), hypocitraturia (abnormally low urinary citrate), and renal tubular acidosis (a condition where the kidneys fail to adequately acidify the urine). By making urine less acidic and increasing citrate levels, Alkacit reduces the formation of calcium, uric acid, and cystine stones.

Potassium citrate, the active ingredient in Alkacit, has been used in clinical medicine for several decades as a cornerstone of medical management of kidney stone disease. Kidney stones (also known as renal calculi or nephrolithiasis) affect approximately 10–15% of the global population at some point in their lives, and recurrence rates without preventive treatment can exceed 50% within 5–10 years. Potassium citrate therapy addresses one of the most common metabolic risk factors for stone formation: hypocitraturia.

Citrate plays a dual protective role in the urinary tract. First, it acts as a natural inhibitor of calcium crystal formation. In the kidneys, citrate binds to calcium ions, forming a soluble complex that prevents calcium from combining with oxalate or phosphate to form insoluble crystite (calcium oxalate or calcium phosphate) crystals. Second, when potassium citrate is metabolized, it produces bicarbonate, which raises urinary pH. This alkalinization is particularly beneficial for dissolving uric acid stones, which form in acidic urine (pH below 5.5), and for reducing the formation of cystine stones.

The extended-release tablet formulation of Alkacit is specifically designed to release potassium citrate gradually over several hours. This gradual release minimizes the gastrointestinal side effects that are common with immediate-release potassium preparations, such as nausea, abdominal pain, and diarrhea. The wax matrix of the tablet passes through the gastrointestinal tract and may be visible in the stool, which is entirely normal and does not indicate that the medication has not been absorbed.

Alkacit is also available as an oral solution, which provides more flexible dosing and may be preferred for patients who have difficulty swallowing tablets. The oral solution has a potassium concentration of 33 mg per milliliter (0.85 mmol K+/ml) and is absorbed more rapidly than the extended-release tablet form.

Approved Indications

Alkacit is indicated for the following conditions, each of which involves a disturbance in urinary chemistry that promotes stone formation or reflects an underlying metabolic disorder:

• Treatment and prevention of kidney stones (nephrolithiasis): Potassium citrate is recommended by the European Association of Urology (EAU) and the American Urological Association (AUA) as first-line pharmacological therapy for patients with recurrent calcium oxalate, calcium phosphate, uric acid, or cystine stones, particularly when hypocitraturia is present. Randomized controlled trials have demonstrated a 75–85% reduction in stone recurrence with potassium citrate therapy.
• Hypocitraturia: This metabolic condition is characterized by abnormally low levels of citrate excreted in the urine (defined as less than 320 mg/day in adults). Hypocitraturia is present in approximately 20–60% of patients with recurrent kidney stones and is an independent risk factor for stone formation. Potassium citrate directly corrects this deficiency by providing exogenous citrate that is excreted in the urine.
• Renal tubular acidosis (RTA): This is a group of disorders in which the kidneys fail to adequately excrete acid, leading to metabolic acidosis. In distal (Type 1) RTA, the inability to acidify urine leads to alkaline urine, hypocitraturia, and a high risk of calcium phosphate stone formation and nephrocalcinosis. Potassium citrate provides alkali to correct the acidosis while also replacing potassium losses that commonly occur in this condition.

What Should You Know Before Taking Alkacit?

Before taking Alkacit, your doctor must evaluate your kidney function, blood potassium levels, and urine composition. Alkacit is contraindicated in patients with severe kidney impairment, hyperkalemia, gastrointestinal obstruction, untreated diabetes, or adrenal insufficiency. The medication carries a risk of potentially fatal hyperkalemia, particularly when combined with other potassium-raising drugs, and requires regular blood monitoring throughout treatment.

Potassium citrate is a powerful therapeutic agent, but because each Alkacit tablet contains a significant amount of potassium (390 mg per tablet), careful patient selection and ongoing monitoring are essential. The risks are particularly elevated in patients with impaired kidney function, as the kidneys are the primary route of potassium excretion. Understanding the contraindications, warnings, and precautions is critical for safe use of this medication.

Contraindications

You must not take Alkacit if you have any of the following conditions. These represent absolute contraindications where the risks of treatment clearly outweigh any potential benefits:

• Allergy to potassium citrate: If you have a known hypersensitivity to potassium citrate or any other ingredient in Alkacit, you should not take this medication.
• Severe kidney impairment: Patients with significantly reduced kidney function cannot adequately excrete potassium, leading to dangerous accumulation in the blood (hyperkalemia). Your doctor will assess your kidney function before starting treatment.
• Hyperkalemia (high blood potassium): If your blood potassium level is already elevated, adding more potassium through Alkacit could push levels to dangerous or fatal heights, causing cardiac arrhythmias and cardiac arrest.
• Active or persistent urinary tract infection: Urinary tract infections caused by urease-producing bacteria (such as Proteus species) can make urine more alkaline. Further alkalinization with potassium citrate could promote the formation of struvite (infection) stones.
• Significant or complete urinary tract obstruction: If urine flow is blocked, medications that alter urine composition cannot be properly excreted, and the underlying obstruction must be treated first.
• Severe heart failure: Patients with severe cardiac dysfunction are at increased risk of hyperkalemia-related cardiac events and may not tolerate additional potassium loading.
• Untreated diabetes mellitus: Uncontrolled diabetes can impair potassium regulation and increase the risk of hyperkalemia. Diabetes should be adequately managed before starting potassium citrate therapy.
• Adrenal insufficiency (Addison’s disease): The adrenal glands produce aldosterone, which regulates potassium excretion. Without adequate aldosterone, potassium accumulates in the blood. Untreated adrenal insufficiency is an absolute contraindication.
• Metabolic or respiratory alkalosis: If your blood is already too alkaline, further alkali loading with potassium citrate could worsen the acid-base disturbance.
• Peptic ulcer disease: The potassium content may irritate an existing ulcer, potentially causing bleeding or perforation.
• Delayed gastric emptying: Conditions that slow stomach emptying (gastroparesis) can cause the extended-release tablet to remain in the stomach longer than intended, increasing the risk of local irritation and ulceration.
• Gastrointestinal obstruction: Any blockage in the digestive tract prevents proper passage and absorption of the medication and can lead to local tissue damage.

Warnings and Precautions

Speak with your doctor or pharmacist before taking Alkacit if any of the following apply to you. These situations require additional caution and closer monitoring:

Hyperkalemia risk: This is the most serious risk associated with Alkacit. Hyperkalemia (serum potassium above 5.5 mmol/L) can cause life-threatening cardiac arrhythmias, including ventricular fibrillation and cardiac arrest. The risk is highest in patients with any degree of kidney impairment, in those taking other medications that raise potassium levels, and in elderly patients. Your doctor will check your blood potassium levels and kidney function regularly—typically every 4 months during treatment. If you develop symptoms of hyperkalemia (muscle weakness, confusion, difficulty speaking, slow heartbeat), seek emergency medical care immediately.

Conditions that impair potassium excretion: If you have any condition that reduces your body’s ability to excrete potassium through the kidneys, Alkacit may cause dangerous potassium accumulation. This includes chronic kidney disease (even mild-to-moderate), diabetic nephropathy, and conditions that reduce aldosterone production or action.

Severe liver impairment: If you have significantly reduced liver function, Alkacit should be used with particular caution. The liver plays a role in metabolizing citrate to bicarbonate, and impaired liver function may alter the expected pharmacological effects of the medication.

Gastrointestinal considerations: The extended-release tablet formulation reduces but does not eliminate the risk of gastrointestinal irritation. If you have a history of gastrointestinal bleeding, ulceration, or conditions that affect gut motility, discuss these with your doctor before starting Alkacit. Always take the tablets with meals or within 30 minutes after eating to reduce gastric irritation.

Pregnancy and Breastfeeding

If you are pregnant, planning to become pregnant, or breastfeeding, consult your doctor before taking Alkacit. Potassium citrate should only be used during pregnancy when your doctor determines it is absolutely necessary. If treatment is deemed essential, you will be closely monitored throughout your pregnancy to ensure safe potassium levels.

Alkacit can be used during breastfeeding. Potassium and citrate are naturally occurring substances in the human body and in breast milk. At recommended therapeutic doses, the additional potassium from Alkacit is not expected to significantly alter breast milk composition or pose a risk to the nursing infant. However, inform your doctor if you are breastfeeding so that appropriate monitoring can be arranged.

Driving and Operating Machinery

Alkacit does not affect your ability to drive or operate machinery. The medication works locally in the urinary system and does not have central nervous system effects. You remain responsible for assessing your own fitness to drive; if you experience any unusual symptoms while taking Alkacit, consult your doctor before driving.

How Does Alkacit Interact with Other Drugs?

Alkacit can interact with many commonly prescribed medications, primarily through its potassium content and its ability to alkalinize urine. The most dangerous interactions involve other drugs that raise blood potassium levels, including ACE inhibitors, angiotensin II receptor blockers (ARBs), potassium-sparing diuretics, and NSAIDs. Always inform your doctor about all medications you are taking, including over-the-counter drugs and supplements.

Drug interactions with Alkacit occur through two main mechanisms. First, because each tablet contains 390 mg of potassium, any other medication or supplement that increases blood potassium levels creates a cumulative risk of hyperkalemia. Second, by alkalinizing the urine, Alkacit can alter the renal elimination of other drugs whose excretion is pH-dependent. Understanding these interactions is essential for the safe use of this medication alongside other treatments.

Drugs That Increase Potassium Levels

The following medications can raise blood potassium levels when used together with Alkacit. Combining any of these with Alkacit significantly increases the risk of hyperkalemia and requires careful monitoring:

Drugs Affected by Urinary Alkalinization

By raising urinary pH, Alkacit can alter the excretion and effectiveness of several other medications. When urine becomes more alkaline, drugs that are weak bases become less ionized and are reabsorbed more readily by the renal tubules, resulting in higher blood levels and prolonged effects:

Other Important Interactions

Anticholinergic medications: Drugs that slow gastrointestinal motility (such as atropine, hyoscine, and some antidepressants with anticholinergic properties) can increase the time the extended-release tablet remains in contact with the stomach or intestinal lining, increasing the risk of local irritation and peptic ulceration.

Alcohol: You should not drink alcohol while taking Alkacit extended-release tablets. Alcohol can disrupt the extended-release mechanism, causing the full dose of potassium citrate to be released too quickly. This rapid release can overwhelm the gastrointestinal tract, increasing the risk of severe irritation, nausea, and vomiting.

What Is the Correct Dosage of Alkacit?

The recommended starting dose for Alkacit depends on the severity of hypocitraturia. For severe hypocitraturia (urinary citrate below 150 mg/day), the starting dose is 6 tablets daily (60 mEq) divided into 3 doses. For mild hypocitraturia (urinary citrate above 150 mg/day), the starting dose is 3 tablets daily (30 mEq) divided into 3 doses. The maximum dose is 10 tablets daily (100 mEq). Always take tablets with meals.

Alkacit dosing is individualized based on the severity of your condition, your urinary citrate levels, and your response to treatment. Your doctor will determine the optimal dose by measuring urinary citrate excretion and urine pH at baseline and during treatment. The goal is to achieve a 24-hour urinary citrate excretion above 320 mg (for stone prevention) and a urine pH between 6.0 and 7.0. Doses are always divided into three daily doses taken with meals to optimize absorption and minimize gastrointestinal side effects.

Adults

How to Take Alkacit

For optimal effectiveness and safety, follow these instructions carefully:

• Timing: Take Alkacit with meals or within 30 minutes after eating. Taking the medication with food reduces the risk of gastrointestinal irritation and helps slow the release of potassium into the stomach.
• Swallow whole: The extended-release tablets must be swallowed whole with a full glass of water. Do not crush, chew, break, or dissolve the tablets. Destroying the extended-release matrix causes the entire dose to be released at once, which can cause severe irritation and ulceration of the mouth, throat, and stomach.
• Avoid alcohol: Do not drink alcohol while taking Alkacit, as alcohol can cause premature release of the medication from the extended-release tablet.
• Follow a low-sodium diet: Reduce your salt intake by avoiding high-sodium foods and not adding table salt to meals. Excess sodium increases urinary calcium excretion and partially counteracts the stone-preventing benefits of citrate therapy.
• Increase fluid intake: Aim to drink at least 2–3 liters of fluid daily (primarily water) to maintain dilute urine. Adequate hydration is a cornerstone of kidney stone prevention and helps maximize the effectiveness of Alkacit.

Moderate Kidney Impairment

If you have moderately reduced kidney function, your doctor may still prescribe Alkacit, but at a lower dose and with more frequent monitoring. Kidney function tests (serum creatinine, estimated glomerular filtration rate) and serum potassium levels will be checked regularly—potentially as often as every 1–2 months initially—to ensure safe treatment. Your doctor will adjust the dose based on your individual response and laboratory results.

Liver Impairment

If you have liver disease, Alkacit should be used with caution. The liver metabolizes citrate to bicarbonate, and impaired liver function may reduce the expected alkalinizing effect or alter potassium handling. Your doctor will monitor your acid-base balance and potassium levels closely.

Missed Dose

If you forget to take a dose, skip the missed dose entirely. Take your next dose at the normal scheduled time. Do not take a double dose to compensate for a missed one. Taking extra tablets at once increases the risk of gastrointestinal irritation and could temporarily raise potassium levels higher than desired.

Overdose

If you take more Alkacit than prescribed, or if a child accidentally ingests the medication, contact your local poison control center or emergency services immediately—even if there are no immediate symptoms. Potassium citrate overdose can cause severe hyperkalemia, which may develop gradually or in stages.

Stopping Treatment

Do not stop taking Alkacit unless your doctor advises you to do so. Kidney stone prevention often requires long-term treatment, and stopping the medication can allow stone-forming conditions to return. Your doctor will decide when it is appropriate to discontinue treatment based on your 24-hour urinary chemistry results, imaging studies, and overall clinical picture.

What Are the Side Effects of Alkacit?

Like all medications, Alkacit can cause side effects, although not everyone experiences them. The most common side effects are gastrointestinal in nature, including abdominal pain, nausea, diarrhea, and bloating. The most serious potential side effect is hyperkalemia (dangerously high blood potassium), which can cause muscle weakness, confusion, irregular heartbeat, and in severe cases, cardiac arrest. Seek immediate medical attention if you experience symptoms of hyperkalemia.

The side effect profile of Alkacit is largely determined by two factors: the potassium content (which carries systemic risks, primarily hyperkalemia) and the local effects of the tablet on the gastrointestinal tract. The extended-release formulation significantly reduces gastrointestinal side effects compared to immediate-release potassium citrate preparations, but some degree of stomach and intestinal irritation is common, particularly at higher doses. Below is a comprehensive overview of reported side effects, organized by frequency.

Wax tablet remnants: You may notice remnants of the wax tablet matrix in your stool. This is entirely normal and expected. The wax shell is not absorbed by the body; it passes through the gastrointestinal tract after the medication has been released. Do not be concerned if you see these remnants.

Minimizing gastrointestinal side effects: Most gastrointestinal side effects can be reduced by taking Alkacit with meals, drinking plenty of water when swallowing the tablet, and ensuring you never exceed the prescribed dose. If gastrointestinal symptoms are bothersome, your doctor may reduce the dose temporarily or split the daily dose into smaller, more frequent portions. Switching from the extended-release tablet to the oral solution may also improve tolerability in some patients.

How Should You Store Alkacit?

Store Alkacit in its original packaging, protected from moisture, and out of the sight and reach of children. Do not use the medication after the expiration date printed on the outer carton and bottle label. Dispose of unused or expired medication responsibly through your pharmacy—do not flush it down the toilet or discard it with household waste.

Proper storage of Alkacit ensures the medication remains effective and safe throughout its shelf life. The extended-release tablet formulation is sensitive to moisture, which can compromise the modified-release mechanism and alter the drug’s release profile. Following these storage guidelines protects both the medication’s integrity and the safety of household members.

• Keep out of reach of children: Store Alkacit in a location that is not accessible to children. Accidental ingestion of potassium citrate by a child can cause serious hyperkalemia.
• Store in original packaging: The tablets are packaged in a plastic bottle with a child-resistant safety cap, within an outer carton. Keep the tablets in this original packaging to protect them from moisture.
• Protect from moisture: Alkacit is moisture-sensitive. Do not store it in the bathroom or other humid environments. Ensure the bottle cap is tightly closed after each use.
• Check expiration date: Do not use Alkacit after the expiry date (EXP) printed on the carton and bottle label. The expiry date refers to the last day of the stated month.
• Proper disposal: Do not dispose of medications via wastewater or household waste. Return unused or expired Alkacit to your pharmacy for safe disposal. These measures help protect the environment.

What Does Alkacit Contain?

Each Alkacit extended-release tablet contains 1,080 mg (10 mEq) of potassium citrate as the active ingredient, equivalent to 390 mg of elemental potassium. The tablets are cream-colored to yellow, oval, biconvex, uncoated, and approximately 18.5 mm in size. They are supplied in bottles of 100 tablets.

Understanding the composition of your medication helps you identify the tablets and be aware of all substances you are taking. Below is detailed information about the active ingredient and the physical characteristics of Alkacit.

Active Ingredient

The active substance is potassium citrate. Each extended-release tablet contains 1,080 mg of potassium citrate, which is equivalent to 10 milliequivalents (mEq) and provides 390 mg of elemental potassium. Potassium citrate (chemical formula: K₃C₆H₅O₇) is the tripotassium salt of citric acid. It is a white, hygroscopic crystalline powder that is freely soluble in water.

Physical Appearance

Alkacit tablets are cream-colored to yellow, oval-shaped, biconvex (curved on both sides), and uncoated. Each tablet measures approximately 18.5 mm in length. The tablets have a wax matrix that controls the release of potassium citrate. As noted above, this wax matrix is not absorbed and may be visible in the stool.

Packaging

Alkacit is supplied in bottles of 100 extended-release tablets. The tablets are packaged in a plastic bottle sealed with a child-resistant safety cap, and the bottle is placed within an outer carton. The oral solution formulation is available separately with a potassium concentration of 33 mg/ml (0.85 mmol K+/ml).